and were more symptomatic (NYHA≥II 55% vs. 31% p<0.001 Objective: To determine the predictors of mortality in patients with severe Tricuspid Regurgitation (TR). Methods: Consecutive patients with severe TR examined at a tertiary care medical center during 36 months were identified [341 patients (239 hospitalized); age 73±14 yrs, 36% male]. The relationships between demographics, echocardiographic parameters, clinical characteristics and mortality were examined. Results: During a median follow-up period of 21 months (interquartile range 4-34), 178 patients (52%) died. Survival was significantly different between hospitalized and non-hospitalized patients at 1 yr (57% versus 86%, respectively) and 3 yrs of follow-up (34% versus 73%) (P<0.001; graph). By multivariate Cox regression analysis -Right Ventricular (RV) dysfunction (moderate or severe, present in 19% of patients) (Hazard Ratio [HR] 1.9, 95% Confidence Interval [CI] 1.2-3.0) and Pulmonary Artery Pressure (PAP) > 55 mmHg (median PAP of study population; HR 1.6, CI 1.1-2.5) were independent predictors of mortality, adjusting for age, gender, and hospitalization status. Among hospitalized patients (clinical data were available for analysis) -Charlson comorbidity index ≥3 (present in 55% of patients) was an additional independent predictor of mortality (HR 1.6, CI 1.1-2.5), whereas severe heart failure (NYHA class III-IV) was not. The mortality in a minority of hospitalized patients (n=40) without the above risk factors (RV dysfunction, pulmonary hypertension, or significant comorbidity) was markedly lower than in patients with at least on risk factor (33% versus 69%, respectively, P<0.001).
Objective: To determine the predictors of mortality in patients with severe Tricuspid Regurgitation (TR). Methods: Consecutive patients with severe TR examined at a tertiary care medical center during 36 months were identified [341 patients (239 hospitalized); age 73±14 yrs, 36% male]. The relationships between demographics, echocardiographic parameters, clinical characteristics and mortality were examined. Results: During a median follow-up period of 21 months (interquartile range 4-34), 178 patients (52%) died. Survival was significantly different between hospitalized and non-hospitalized patients at 1 yr (57% versus 86%, respectively) and 3 yrs of follow-up (34% versus 73%) (P<0.001; graph). By multivariate Cox regression analysis -Right Ventricular (RV) dysfunction (moderate or severe, present in 19% of patients) (Hazard Ratio [HR] 1.9, 95% Confidence Interval [CI] 1.2-3.0) and Pulmonary Artery Pressure (PAP) > 55 mmHg (median PAP of study population; HR 1.6, CI 1.1-2.5) were independent predictors of mortality, adjusting for age, gender, and hospitalization status. Among hospitalized patients (clinical data were available for analysis) -Charlson comorbidity index ≥3 (present in 55% of patients) was an additional independent predictor of mortality (HR 1.6, CI 1.1-2.5), whereas severe heart failure (NYHA class III-IV) was not. The mortality in a minority of hospitalized patients (n=40) without the above risk factors (RV dysfunction, pulmonary hypertension, or significant comorbidity) was markedly lower than in patients with at least on risk factor (33% versus 69%, respectively, P<0.001).
Conclusions: Short-term mortality is very high in patients with severe TR, specifically in hospitalized patients and in the presence of echocardiographic and clinical risk markers.
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Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long term follow-up Background: The presence of a right ventricular (RV) lead is a potential cause of tricuspid regurgitation (TR). However, the clinical impact of significant leadinduced TR is not yet elucidated. We aimed at evaluating the effect of significant lead-induced TR on 1) cardiac performance and 2) long-term outcome of patients with cardioverter-defibrillator or pacemaker. Methods: A total of 239 cardioverter-defibrillator (n=191) or pacemaker (n=48) recipients (age 60±14 years, 77% male), with an echocardiographic evaluation before and within 1-1.5 years after device implantation, were included. Leadinduced significant TR was defined as a TR worsening and reaching a grade ≥2 at follow-up echocardiography. During long-term follow-up (median 58, IQR 35-76 months) all-cause mortality and heart failure related events were recorded. Results: Before device implantation, most patients had TR grade 1 or 2 (64%) or no TR (34%), but after lead placement, significant TR was observed in 91 patients (38%). Changes in cardiac chambers size and function at follow-up were similar between patients with and without significant lead-induced TR, except for increased RV diastolic area (17±6 vs. 16±5, p=0.009), right atrial diameter (39±10 vs. 36±8mm, p<0.001) and pulmonary arterial pressures (41±15 vs. 33±10mmHg, p<0.001) in patients with significant lead-induced TR. Patients with significant lead-induced TR showed worse long-term outcome in terms of overall survival (p=0.038) and/or combined with heart failure related events (p=0.017). At multivariate analysis, significant lead-induced TR was independently associated with all-cause mortality (HR 1.75, 95% CI: 1.01-3.04, p=0.047) together with age, LV ejection fraction and RV pacing percentage.
Overall survival

Conclusion:
Lead-induced significant TR is associated with long-term poor prognosis. Hypertension is a known risk factor for cardiovascular outcomes such as acute coronary syndrome (ACS). Influence of antecedent hypertension on the long-term survival of ACS patients according to the type of ACS is not well characterized. Methods: We included 20,504 patients with ACS in the Eastern Danish Heart Mortality in STEMI patients
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